1
|
Reiter RJ: Pineal melatonin: cell biology
of its synthesis and of its physiological interactions. Endocr Rev.
12:151–180. 1991. View Article : Google Scholar : PubMed/NCBI
|
2
|
Reiter RJ, Tan DX and Fuentes-Broto L:
Melatonin: a multitasking molecule. Prog Brain Res. 181:127–151.
2010. View Article : Google Scholar : PubMed/NCBI
|
3
|
Vanëcek J: Melatonin binding sites. J
Neurochem. 51:1436–1440. 1988.
|
4
|
Cajochen C, Kräuchi K and Wirz-Justice A:
Role of melatonin in the regulation of human circadian rhythms and
sleep. J Neuroendocrinol. 15:432–437. 2003. View Article : Google Scholar : PubMed/NCBI
|
5
|
Acuña-Castroviejo D, Reiter RJ,
Menéndez-Peláez A, Pablos MI and Burgos A: Characterization of
high-affinity melatonin binding sites in purified cell nuclei of
rat liver. J Pineal Res. 16:100–112. 1994.PubMed/NCBI
|
6
|
Jetten AM, Kurebayashi S and Ueda E: The
ROR nuclear orphan receptor subfamily: critical regulators of
multiple biological processes. Prog Nucleic Acid Res Mol Biol.
69:205–247. 2001. View Article : Google Scholar : PubMed/NCBI
|
7
|
Carlberg C, Hooft van Huijsduijnen R,
Staple JK, DeLamarter JF and Becker-André M: RZRs, a new family of
retinoid-related orphan receptors that function as both monomers
and homodimers. Mol Endocrinol. 8:757–770. 1994.
|
8
|
Reiter RJ, Paredes SD, Manchester LC and
Tan DX: Reducing oxidative/nitrosative stress: a newly-discovered
genre for melatonin. Crit Rev Biochem Mol Biol. 44:175–200. 2009.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Antón-Tay F, Ramírez G, Martínez I and
Benítez-King G: In vitro stimulation of protein kinase C by
melatonin. Neurochem Res. 23:601–606. 1998.PubMed/NCBI
|
10
|
Soto-Vega E, Meza I, Ramírez-Rodríguez G
and Benitez-King G: Melatonin stimulates calmodulin phosphorylation
by protein kinase C. J Pineal Res. 37:98–106. 2004. View Article : Google Scholar : PubMed/NCBI
|
11
|
Turjanski AG, Estrin DA, Rosenstein RE,
McCormick JE, Martin SR, Pastore A, Biekofsky RR and Martorana V:
NMR and molecular dynamics studies of the interaction of melatonin
with calmodulin. Protein Sci. 13:2925–2938. 2004. View Article : Google Scholar : PubMed/NCBI
|
12
|
Macías M, Escames G, Leon J, Coto A, Sbihi
Y, Osuna A and Acuña-Castroviejo D: Calreticulin-melatonin. An
unexpected relationship. Eur J Biochem. 270:832–840.
2003.PubMed/NCBI
|
13
|
Nosjean O, Ferro M, Coge F, Beauverger P,
Henlin JM, Lefoulon F, Fauchere JL, Delagrange P, Canet E and
Boutin JA: Identification of the melatonin-binding site MT3 as the
quinone reductase 2. J Biol Chem. 275:31311–31317. 2000. View Article : Google Scholar : PubMed/NCBI
|
14
|
Tan DX, Manchester LC, Hardeland R,
Lopez-Burillo S, Mayo JC, Sainz RM and Reiter RJ: Melatonin: a
hormone, a tissue factor, an autocoid, a paracoid, and an
antioxidant vitamin. J Pineal Res. 34:75–78. 2003. View Article : Google Scholar : PubMed/NCBI
|
15
|
Hardeland R, Tan DX and Reiter RJ:
Kynuramines, metabolites of melatonin and other indoles: the
resurrection of an almost forgotten class of biogenic amines. J
Pineal Res. 47:109–126. 2009. View Article : Google Scholar
|
16
|
Luchetti F, Canonico B, Betti M,
Arcangeletti M, Pilolli F, Piroddi M, Canesi L, Papa S and Galli F:
Melatonin signaling and cell protection function. FASEB J.
24:3603–3624. 2010. View Article : Google Scholar : PubMed/NCBI
|
17
|
Wiechmann AF and Summers JA: Circadian
rhythms in the eye: the physiological significance of melatonin
receptors in ocular tissues. Prog Retin Eye Res. 27:137–160. 2008.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Scher J, Wankiewicz E, Brown GM and
Fujieda H: MT(1) melatonin receptor in the human retina: expression
and localization. Invest Ophthalmol Vis Sci. 43:889–897.
2002.PubMed/NCBI
|
19
|
Itoh MT, Ishizuka B, Kuribayashi Y,
Amemiya A and Sumi Y: Melatonin, its precursors, and synthesizing
enzyme activities in the human ovary. Mol Hum Reprod. 5:402–408.
1999. View Article : Google Scholar : PubMed/NCBI
|
20
|
Tamura H, Nakamura Y, Korkmaz A,
Manchester LC, Tan DX, Sugino N and Reiter RJ: Melatonin and the
ovary: physiological and pathophysiological implications. Fertil
Steril. 92:328–343. 2009. View Article : Google Scholar : PubMed/NCBI
|
21
|
Bubenik GA: Localization, physiological
significance and possible clinical implication of gastrointestinal
melatonin. Biol Signals Recept. 10:350–366. 2001. View Article : Google Scholar : PubMed/NCBI
|
22
|
Konturek SJ, Konturek PC, Brzozowska I,
Pawlik M, Sliwowski Z, Cześnikiewicz-Guzik M, Kwiecień S,
Brzozowski T, Bubenik GA and Pawlik WW: Localization and biological
activities of melatonin in intact and diseased gastrointestinal
tract (GIT). J Physiol Pharmacol. 58:381–405. 2007.PubMed/NCBI
|
23
|
Carrillo-Vico A, Calvo JR, Abreu P,
Lardone PJ, García-Muriño S, Reiter RJ and Guerrero JM: Evidence of
melatonin synthesis by human lymphocytes and its physiological
significance: possible role as intracrine, autocrine, and/or
paracrine substance. FASEB J. 18:537–539. 2004.
|
24
|
Laakso ML, Porkka-Heiskanen T, Alila A,
Stenberg D and Johansson G: Correlation between salivary and serum
melatonin: dependence on serum melatonin levels. J Pineal Res.
9:39–50. 1990.
|
25
|
Kennaway DJ and Voultsios A: Circadian
rhythm of free melatonin in human plasma. J Clin Endocrinol Metab.
83:1013–1015. 1998.
|
26
|
Nowak R, McMillen IC, Redman J and Short
RV: The correlation between serum and salivary melatonin
concentrations and urinary 6-hydroxymelatonin sulphate excretion
rates: two non-invasive techniques for monitoring human circadian
rhythmicity. Clin Endocrinol (Oxf). 27:445–452. 1987. View Article : Google Scholar
|
27
|
Tan DX, Manchester LC, Reiter RJ, Plummer
BF, Hardies LJ, Weintraub ST, Vijayalaxmi and Shepherd AM: A novel
melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in
vivo hydroxyl radical generation. Biochem Biophys Res Commun.
253:614–620. 1998. View Article : Google Scholar : PubMed/NCBI
|
28
|
Mediavilla MD, Sanchez-Barcelo EJ, Tan DX,
Manchester L and Reiter RJ: Basic mechanisms involved in the
anti-cancer effects of melatonin. Curr Med Chem. 17:4462–4481.
2010. View Article : Google Scholar : PubMed/NCBI
|
29
|
Ravindra T, Lakshmi NK and Ahuja YR:
Melatonin in pathogenesis and therapy of cancer. Indian J Med Sci.
60:523–535. 2006. View Article : Google Scholar : PubMed/NCBI
|
30
|
Jung-Hynes B, Reiter RJ and Ahmad N:
Sirtuins, melatonin and circadian rhythms: building a bridge
between aging and cancer. J Pineal Res. 48:9–19. 2010. View Article : Google Scholar : PubMed/NCBI
|
31
|
Benítez-King G, Soto-Vega E and
Ramírez-Rodriguez G: Melatonin modulates microfilament phenotypes
in epithelial cells: implications for adhesion and inhibition of
cancer cell migration. Histol Histopathol. 24:789–799.
2009.PubMed/NCBI
|
32
|
Cos S, González A, Martínez-Campa C,
Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ:
Estrogen-signaling pathway: a link between breast cancer and
melatonin oncostatic actions. Cancer Detect Prev. 30:118–128. 2006.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Cos S, González A, Martínez-Campa C,
Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Melatonin
as a selective estrogen enzyme modulator. Curr Cancer Drug Targets.
8:691–702. 2008. View Article : Google Scholar : PubMed/NCBI
|
34
|
Rodriguez C, Mayo JC, Sainz RM, Antolín I,
Herrera F, Martín V and Reiter RJ: Regulation of antioxidant
enzymes: a significant role for melatonin. J Pineal Res. 36:1–9.
2004. View Article : Google Scholar : PubMed/NCBI
|
35
|
Reiter RJ, Tan DX, Osuna C and Gitto E:
Actions of melatonin in the reduction of oxidative stress. A
review. J Biomed Sci. 7:444–458. 2000. View Article : Google Scholar : PubMed/NCBI
|
36
|
Molis TM, Spriggs LL and Hill SM:
Modulation of estrogen receptor mRNA expression by melatonin in
MCF-7 human breast cancer cells. Mol Endocrinol. 8:1681–1690.
1994.PubMed/NCBI
|
37
|
Rato AG, Pedrero JG, Martinez MA, del Rio
B, Lazo PS and Ramos S: Melatonin blocks the activation of estrogen
receptor for DNA binding. FASEB J. 13:857–868. 1999.PubMed/NCBI
|
38
|
Sainz RM, Mayo JC, Rodriguez C, Tan DX,
Lopez-Burillo S and Reiter RJ: Melatonin and cell death:
differential actions on apoptosis in normal and cancer cells. Cell
Mol Life Sci. 60:1407–1426. 2003. View Article : Google Scholar : PubMed/NCBI
|
39
|
Leon-Blanco MM, Guerrero JM, Reiter RJ,
Calvo JR and Pozo D: Melatonin inhibits telomerase activity in the
MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res.
35:204–211. 2003. View Article : Google Scholar : PubMed/NCBI
|
40
|
Park SY, Jang WJ, Yi EY, Jang JY, Jung Y,
Jeong JW and Kim YJ: Melatonin suppresses tumor angiogenesis by
inhibiting HIF-1alpha stabilization under hypoxia. J Pineal Res.
48:178–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
41
|
Szczepanik M: Melatonin and its influence
on immune system. J Physiol Pharmacol. 58(Suppl 6): 115–124.
2007.
|
42
|
Dubocovich ML and Markowska M: Functional
MT1 and MT2 melatonin receptors in mammals. Endocrine. 27:101–110.
2005. View Article : Google Scholar : PubMed/NCBI
|
43
|
Dubocovich ML, Cardinali DP,
Guardiola-Lemaitre B, Hagan RM, Sugden D, Vanhoutte PM and Yocca
FD: The IUPHAR compendium of receptor characterization and
classification. Melatonin Receptors. IUPHAR Media; London: pp.
187–193. 1998
|
44
|
Reppert SM: Melatonin receptors: molecular
biology of a new family of G protein-coupled receptors. J Biol
Rhythms. 12:528–531. 1997. View Article : Google Scholar : PubMed/NCBI
|
45
|
von Gall C, Stehle JH and Weaver DR:
Mammalian melatonin receptors: molecular biology and signal
transduction. Cell Tissue Res. 309:151–162. 2002.PubMed/NCBI
|
46
|
Ivanova EA, Bechtold DA, Dupré SM,
Brennand J, Barrett P, Luckman SM and Loudon AS: Altered metabolism
in the melatonin-related receptor (GPR50) knockout mouse. Am J
Physiol Endocrinol Metab. 294:E176–E182. 2008. View Article : Google Scholar : PubMed/NCBI
|
47
|
Sidibe A, Mullier A, Chen P, Baroncini M,
Boutin JA, Delagrange P, Prevot V and Jockers R: Expression of the
orphan GPR50 protein in rodent and human dorsomedial hypothalamus,
tanycytes and median eminence. J Pineal Res. 48:263–269. 2010.
View Article : Google Scholar : PubMed/NCBI
|
48
|
Civelli O, Saito Y, Wang Z, Nothacker HP
and Reinscheid RK: Orphan GPCRs and their ligands. Pharmacol Ther.
110:525–532. 2006. View Article : Google Scholar : PubMed/NCBI
|
49
|
Levoye A, Dam J, Ayoub MA, Guillaume JL,
Couturier C, Delagrange P and Jockers R: The orphan GPR50 receptor
specifically inhibits MT1 melatonin receptor function through
heterodimerization. EMBO J. 25:3012–3023. 2006. View Article : Google Scholar
|
50
|
Tan DX, Manchester LC, Terron MP, Flores
LJ, Tamura H and Reiter RJ: Melatonin as a naturally occurring
co-substrate of quinone reductase-2, the putative MT3 melatonin
membrane receptor: hypothesis and significance. J Pineal Res.
43:317–320. 2007. View Article : Google Scholar : PubMed/NCBI
|
51
|
Boutin JA, Marcheteau E, Hennig P,
Moulharat N, Berger S, Delagrange P, Bouchet JP and Ferry G:
MT3/QR2 melatonin binding site does not use melatonin as a
substrate or a co-substrate. J Pineal Res. 45:524–531. 2008.
View Article : Google Scholar
|
52
|
Ha PK and Califano JA: Promoter
methylation and inactivation of tumour-suppressor genes in oral
squamous-cell carcinoma. Lancet Oncol. 7:77–82. 2006. View Article : Google Scholar
|
53
|
Nakamura E, Kozaki K, Tsuda H, Suzuki E,
Pimkhaokham A, Yamamoto G, Irie T, Tachikawa T, Amagasa T, Inazawa
J and Imoto I: Frequent silencing of a putative tumor suppressor
gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell
carcinoma. Cancer Sci. 99:1390–1400. 2008. View Article : Google Scholar : PubMed/NCBI
|
54
|
Gómez-Moreno G, Guardia J, Ferrera MJ,
Cutando A and Reiter RJ: Melatonin in diseases of the oral cavity.
Oral Dis. 16:242–247. 2010.
|
55
|
Chaiyarit P, Ma N, Hiraku Y, Pinlaor S,
Yongvanit P, Jintakanon D, Murata M, Oikawa S and Kawanishi S:
Nitrative and oxidative DNA damage in oral lichen planus in
relation to human oral carcinogenesis. Cancer Sci. 96:553–559.
2005. View Article : Google Scholar : PubMed/NCBI
|
56
|
Cutando A, Aneiros-Fernández J,
López-Valverde A, Arias-Santiago S, Aneiros-Cachaza J and Reiter
RJ: A new perspective in oral health: potential importance and
actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the
oral cavity. Arch Oral Biol. 56:944–950. 2011. View Article : Google Scholar : PubMed/NCBI
|
57
|
Cutando A, Aneiros-Fernández J,
Aneiros-Cachaza J and Arias-Santiago S: Melatonin and cancer:
current knowledge and its application to oral cavity tumours. J
Oral Pathol Med. 40:593–597. 2011. View Article : Google Scholar : PubMed/NCBI
|